left
Hey There : )
right
company-image

Unlisted Shares

Martin & Harris Essentials

As of July 27, 2024, Martin and Harris Laboratories, Unlisted Shares are trading at ₹970.00 per share, with a 52-week high of ₹1300 and 52-week low of ₹970. The minimun lot size is 200 shares, and the shares are traded on NSDL.

ISIN

INE03VV01015

Face Value

₹ 10

Total Share

39,96,040

Total Income

₹ 205.16 undefined

Profit After Tax

₹ ****

EPS

₹ ****

P/E

****

P/B

****

Market Capitalisation

₹ 387.62 Cr

Enterprise Value

₹ ****

Book Value

₹ 1,402.15

Intrinsic Value

₹ ****

Dividend Yield

0.54 %

Earnings Yield

17.56 %

Sector

Health Care

Sub-sector

Pharmaceuticals

Category

Small Cap

Cashflow - Operations

-₹ 344.02

Cashflow - Financing

-₹ 1.93

Martin & Harris Growth

Compounded Sales Growth

1 Year

4 Year

6 Year

Compounded Profit Growth

1 Year

3 Year

6 Year

Return On Equity

2018

2020

2023

Highlights

image

Established Leadership and Reputation: Founded in 1993, Martin and Harris Laboratories Ltd. has established itself as a leading pharmaceutical company in India, renowned for its research and manufacturing of finished dosage forms.

image

State-of-the-Art Manufacturing Facilities: With state-of-the-art manufacturing facilities strategically located across India, including Roorkee and Gagret, Martin and Harris ensures stringent adherence to WHO GMP guidelines, offering diverse dosage forms and specialty formulations.

image

Innovative R&D Capabilities: The company operates a center of excellence for research and development in Gurugram, focusing on formulation and API development, analytical development, and quality assurance, fostering continuous innovation in pharmaceuticals.

image

Strategic Partnerships and Alliances: Martin and Harris Laboratories has formed strategic alliances with Walter Bushnell for marketing and manufacturing, enhancing their capabilities in innovative pharmaceutical therapies and market expansion.

image

Investment thesis: Martin and Harris Laboratories Ltd., a key player in India's pharmaceutical industry since 1993, excels in producing a wide range of high-quality medicines. Their state-of-the-art facilities in Roorkee and Gagret meet international standards for manufacturing, ensuring top-notch quality. Strategic partnerships, like with Walter Bushnell, help them expand their market reach and innovate. Their research center in Gurugram focuses on developing new medicines and improving existing ones. With a recent 10% increase in revenue and a focus on expanding contract manufacturing, Martin and Harris is well-positioned for continued growth in the competitive pharmaceutical market.

Conclusion: The company's current P/E ratio stands at 5.7x, significantly lower than the average of 45x among comparable peers of similar size. There is potential for enhanced valuation through strategic initiatives such as expanding into international markets and forging partnerships with leading pharmaceutical companies for contract manufacturing.

Business Rating

image

Managment

lock starlock starlock starlock starlock star
image

Accounting Practice

lock starlock starlock starlock starlock star
image

Profatibility

lock starlock starlock starlock starlock star
image

Solvency

lock starlock starlock starlock starlock star
image

Growth

lock starlock starlock starlock starlock star
image

Valuation

lock starlock starlock starlock starlock star

Overall Ratings

lock starlock starlock starlock starlock star

Recommendation

lock starlock starlock starlock starlock star

Our Team

directorImage

Mr. Shanker Laxman Laad

( Director )
directorImage

Mr. Harnam Singh Thakur

( Director )

Quantity

Invest

, Min. Investment: ₹